To contentTo navigationTo search
Logotype

Implantica contemplates a private placement of SDRs

15.04.2021
 | Inside information

Implantica AG (ticker: IMP A SDB) (“Implantica” or the “Company”) has mandated Pareto Securities to evaluate the conditions for a private placement of SDRs corresponding to approximately SEK 500 million (the “Private Placement”), to Swedish and international institutional investors through an accelerated book building procedure.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, HONG KONG, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.

 

The Private Placement is intended to be carried out through an accelerated book building procedure which commences immediately after the announcement of this press release. The Private Placement will comprise newly issued Class A shares in Implantica, represented by Swedish Depository Receipts (“SDRs”). Pricing and allocation in the Private Placement are expected to take place before beginning of trading on Nasdaq First North Premier Growth Market at 09:00 CEST on 16 April 2021. The closing, pricing and allocation of the book building is at the discretion of the Company and may be cancelled at any time. The Company will announce the outcome of the Private Placement when the book building has been completed in a subsequent press release.

  • Approximately 45 percent of the proceeds will be used to:
    • Speed up commercialization by building up the sales organization in key markets in advance of regulatory approvals and reimbursement
    • Eventually explore strategic acquisitions, such as smaller companies selling surgical instruments in selected strategic markets, to expand the network and sales force
  • Approximately 30 percent of the proceeds will be used to:
    • Expedite bringing the eHealth platform to market
    • Expand and enhance the eHealth platform including additional functionality and more treatment fields
  • Approximately 25 percent of the proceeds will be used to:
    • Develop more eHealth-based products such as new stimulation technology and drug delivery from inside the body

The Company believes that the flexibility provided by a non-pre-emptive placement is the most appropriate transaction structure in order to raise capital in a time- and cost-effective manner, whilst also further diversifying and strengthening the Company’s shareholder base. Given that the subscription price in the Private Placement will be determined through an accelerated book building procedure, it is the board of directors’ assessment that the subscription price will be determined in accordance with market conditions.

The Private Placement is subject to, among other things, that Implantica’s board of directors, after the book building procedure has been completed, resolves on the Private Placement, following the authorization to be granted by the Annual General Meeting to be held on 16 April 2021 (the "AGM"). The Company’s largest shareholder Implantica MediSwiss AG, representing the majority of the votes in the Company, has entered into an undertaking to vote in favour of all of the proposals and resolutions by the board of directors relating to the share issue authorization at the AGM 2021.

The Lock-up undertakings from the IPO continue to remain in force. The Company's main shareholder, Implantica MediSwiss AG, undertook not to, during 360 days after the first day of trading of the Company’s SDRs on Nasdaq First North Premier Growth Market, i.e. 21 September 2020, sell or otherwise dispose of any financial instruments in the Company without the consent of Pareto Securities. Certain shareholders of Implantica MediSwiss AG, whose shareholding in Implantica MediSwiss AG exceeds 1.5%, undertook not to, during 360 days after the first day of trading of the Company’s SDRs on Nasdaq First North Premier Growth Market, sell or otherwise dispose of any financial instruments in the Implantica MediSwiss AG without the consent of Pareto Securities. All members of the Board of Directors and senior management are also covered by the lock-up undertaking. The Company is under lock-up until 16 September 2021 and has undertaken to not issue any new shares or sell any of its own shares without the consent of Pareto Securities.

Advisors

Pareto Securities is acting Sole Global Coordinator and Bookrunner in the Offering. Baker McKenzie is the legal advisor to Implantica as to Swedish and Swiss law and Advokatfirman Schjødt is the legal advisor to Pareto Securities in the Offering.

For further information, please contact:

Nicole Pehrsson, Investor Relations, Implantica

Telephone (CH): +41 (0)79 335 09 49

E-mail: nicole.pehrsson@implantica.com

This information is information that Implantica AG is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 15 April 2021 at 17:31 CEST.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from the Company nor from someone else.

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new shares/SDRs. Any investment decision in connection with the Private Placement must be made on the basis of all publicly available information relating to the Company and the Company’s shares/SDRs. Such information has not been independently verified by the Sole Global Coordinator. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. The Sole Global Coordinator is acting for the Company in connection with the transaction and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the transaction or any other matter referred to herein.

This announcement does not constitute a recommendation concerning any investor’s option with respect to the Private Placement. Each investor or prospective investor should conduct his, her or its own investigation, analysis and evaluation of the business and data described in this announcement and publicly available information. The price and value of securities can go down as well as up. Past performance is not a guide to future performance.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into Australia, Hong Kong, Japan, Canada, New Zeeland, Singapore, South Africa, the United States or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorized any offer to the public of shares/SDRs or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Private Placement. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation.

In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company’s intentions, beliefs, or current expectations about and targets for the Company’s future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdaq First North Premier Growth Market's rule book for issuers.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “MiFID II Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares/SDRs in the Company have been subject to a product approval process, which has determined that such shares/SDRs are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the “EU Target Market Assessment”). Solely for the purposes of each manufacturer's product approval process in the United Kingdom, the target market assessment in respect of the shares/SDRs in the Company has led to the conclusion that: (i) the target market for such shares/SDRs is only eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook, and professional clients, as defined in Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MiFIR"); and (ii) all channels for distribution of such shares/SDRs to eligible counterparties and professional clients are appropriate (the “UK Target Market Assessment” and, together with the EU Target Market Assessment, the “Target Market Assessment”). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares/SDRs in the Company may decline and investors could lose all or part of their investment; the shares/SDRs in the Company offer no guaranteed income and no capital protection; and an investment in the shares/SDRs in the Company is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Private Placement. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Sole Global Coordinator will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II or UK MiFIR; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares/SDRs in the Company.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares/SDRs in the Company and determining appropriate distribution channels.

Documents

This website uses cookies to provide the best possible user experience. If you continue without making any changes you allow this. Read more about cookies here